In the case of diabetic nephropathy, sodium-glucose co-transporter 2(SGLT-2) inhibitors (i.e., dapagliflozin) are most frequently mentioned for maintaining kidney function and preventing the progression of diabetic nephropathy to end-stage renal disease (Prattichizzo et al., 2021). The gene discussed is SLC5A2; the disease is diabetic kidney disease.